Gastrointestinal Hormones
Conditions
Brief summary
The distal ileum and proximal colon, where the glucagon-like peptide 1 (GLP-1) releasing cells predominate, are important organs in mediating glycemic control. The proximal colon is not easy to access and the correspond in vivo research remains to be difficult. The investigators intend to recruit subjects who underwent rectal surgery with simultaneous protective ileostomy and evaluate hormone secretion and glycemic excursions via ileostomy glucose or saline infusion, and quantify the glucose absorption rate within the proximal colon.
Interventions
DIETARY_SUPPLEMENTcolonic infusion
colonic glucose or colonic saline infusion
Sponsors
Qilu Hospital of Shandong University
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Male and postmenopausal females aged 18 - 75 years * Body mass index (BMI) 20 - 35 kg/m2 * With protective ileostomy due to benign or malignant rectal surgery
Exclusion criteria
* History of postoperative adjuvant chemotherapy * Other significant illness, including epilepsy, cardiovascular or respiratory disease * Impaired renal or liver function (as assessed by calculated creatinine clearance \< 90 mL/min or abnormal liver function tests (\> 2 times upper limit of normal range)) * Donation of blood within the previous 3 months * Participation in any other research studies within the previous 3 months * Females who are pre-menopausal * Inability to give informed consent * Vegetarians
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| serum or plasma glucagon changes during colonic infusion | 180 minutes | concentration of serum or plasma glucagon (pmol/L) |
| glucose absorption capacity | 180 minutes | estimated glucose absorption rate during colonic glucose infusion |
| serum or plasma GLP-1 changes during colonic infusion | 180 minutes | concentration of serum or plasma GLP-1 (pmol/L) |
| serum or plasma GIP changes during colonic infusion | 180 minutes | concentration of serum or plasma GIP (pmol/L) |
| serum or plasma ghrelin changes during colonic infusion | 180 minutes | concentration of serum or plasma ghrelin (pg/ml) |
| serum or plasma c-peptide changes during colonic infusion | 180 minutes | concentration of serum or plasma c-peptide (pmol/L) |
| serum or plasma insulin changes during colonic infusion | 180 minutes | concentration of serum or plasma insulin (pmol/L) |
Countries
China
Outcome results
None listed